We have demonstrated the effect of galectin-9 in various gastroenterological cancers, such as esophageal cancer [17], hepatocellular carcinoma [18], cholangiocarcinoma [19], and pancreatic cancer [20]. This evidence concerns the gene LGALS9 and cholangiocarcinoma.